CN107468955A - Treat the Chinese medicine and preparation method of urarthritis - Google Patents

Treat the Chinese medicine and preparation method of urarthritis Download PDF

Info

Publication number
CN107468955A
CN107468955A CN201710796097.5A CN201710796097A CN107468955A CN 107468955 A CN107468955 A CN 107468955A CN 201710796097 A CN201710796097 A CN 201710796097A CN 107468955 A CN107468955 A CN 107468955A
Authority
CN
China
Prior art keywords
radix
volatile oil
urarthritis
chinese
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710796097.5A
Other languages
Chinese (zh)
Other versions
CN107468955B (en
Inventor
张琳
李炜玲
隋华
肖楠
何世勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalian Medical University
Original Assignee
Dalian Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalian Medical University filed Critical Dalian Medical University
Priority to CN201710796097.5A priority Critical patent/CN107468955B/en
Publication of CN107468955A publication Critical patent/CN107468955A/en
Application granted granted Critical
Publication of CN107468955B publication Critical patent/CN107468955B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/756—Phellodendron, e.g. corktree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/716—Clematis (leather flower)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention discloses a kind of Chinese medicine for treating urarthritis, is to be made up of the volatile oil and water extract of Chinese herb medicine, the component and mass ratio of the Chinese herb medicine are as follows：Golden cypress 10, rhizoma atractylodis 10, smilax 30, radix glycyrrhizae 10, the root of Chinese clematis 15, the radix paeoniae rubrathe 10, giant knotweed 15, Radix Angelicae Sinensis 10, edible tulip 8, levisticum 10, Radix Codonopsis 15, prepared RADIX ET RHIZOMA RHEI with wine 10.The Pharmacological experiment result shows that the present invention has the function that to treat urarthritis well, with can improve arthroncus caused by urarthritis, inflammatory factor change, Antioxidative Factors change etc. curative effect, various drug forms can be prepared into pharmaceutically acceptable carrier, facilitate clinic to take.Preparation method provided by the invention is workable, low, environmentally friendly, the achievable industrialized production of cost.

Description

Treat the Chinese medicine and preparation method of urarthritis
Technical field
The present invention provides a kind of medicine and preparation method for the treatment of of arthritis, and especially a kind of curative effect is reliable, Small side effects Treatment urarthritis Chinese medicine and preparation method.
Background technology
Urarthritis is a kind of because purine metabolic disturbance, uric acid produce excessively or acatharsia makes serum Uric Acid Concentration Increase and uric acid mineralization caused by it is a kind of with arthralgia, swelling, deformity based on disease.With falling ill, rapid, pain is acute It is strong, delay it is refractory the features such as, make us suffering untold misery, had a strong impact on health and the daily life of people.Colchicin is One of active drug when gout especially severe acute breaks out is treated, but colchicin can neither suppress the generation of uric acid, also The excretion of uric acid can not be promoted.Diarrhoea, vomiting, abdominal cramp are its common adverse reactions, and are the first fingers of toxicity Sign, treatment effective dose cause the comparable doses of gastrointestinal symptom with it.Non-steroid anti-inflammatory drug can not only cause intestines and stomach malicious Property, and adverse reaction can be produced to kidney, central nervous system, hematological system, cardiovascular system, fetus and skin, also Can not two kinds or more take simultaneously.Using glucocorticoid treatment gout, symptom " knock-on " phenomenon easily occurs after withdrawal.Now The medicine of the suppression uric acid generation uniquely listed be allopurinol, generated suitable for uric acid it is excessive, but have liver and bone marrow toxicity with The adverse reactions such as allergy.The medicine for improving uric acid excretion such as probenecid, sulfinpyrazone, Benzbromarone are mainly by suppressing near-end kidney Tubule promotes the reabsorption of uric acid uric acid excretion, and disadvantage is the deposition that can cause urate crystals in urinary tract, triggers Renal colic and kidney function damage.In summary, doctor trained in Western medicine is used for the medicine for treating urarthritis and biological agent often because treating Effect does not comply with one's wishes, or toxic side effect is larger and be difficult to promote or long-term use of.
The content of the invention
The present invention is to solve the above-mentioned technical problem present in prior art, there is provided a kind of curative effect is reliable, side effect The Chinese medicine and preparation method of small treatment urarthritis.
The present invention technical solution be：A kind of Chinese medicine for treating urarthritis, it is characterised in that be by medium-height grass The volatile oil and water extract of medicine are formed, and the component and mass ratio of the Chinese herb medicine are as follows：Golden cypress 10, rhizoma atractylodis 10, smilax 30th, radix glycyrrhizae 10, the root of Chinese clematis 15, the radix paeoniae rubrathe 10, giant knotweed 15, Radix Angelicae Sinensis 10, edible tulip 8, levisticum 10, Radix Codonopsis 15, prepared RADIX ET RHIZOMA RHEI with wine 10.
A kind of preparation method of the medicine of above-mentioned treatment urarthritis, it is characterised in that carry out in accordance with the following steps：
A. by raw material golden cypress, rhizoma atractylodis, smilax, radix glycyrrhizae, the root of Chinese clematis, the radix paeoniae rubrathe, giant knotweed, Radix Angelicae Sinensis, edible tulip, levisticum, Radix Codonopsis and wine Rheum officinale mixing, crush, be placed in round-bottomed flask, add the pure water of 8 times of amounts of total raw material, shaking mixing, soak 30 minutes；
B. round-bottomed flask is connected into volatile oil extractor and reflux condensing tube, autocondensation pipe upper end adds water to be surveyed full of volatile oil Determine the scale part of device and when overflow enters round-bottomed flask untill, then round-bottomed flask is put boiling water is slowly heated in electric jacket And keep water micro-boiling 6 hours, stop heating, place cooling, open volatile oil extractor lower end piston, water is slowly released, receive Collect volatile oil, it is standby；
C. the dregs of a decoction after step b extraction volatile oil are taken, adds the pure water of 8 times of amounts to decoct 2 times, 2 hours every time, filtering, merges filter Liquid, be concentrated under reduced pressure to obtain water extract；
D. it is obtained volatile oil and water extract is well mixed.
The present invention is formulated with the Chinese herb medicine of Small side effects, and each component matches scientific and reasonable, volatile oil and water extraction Thing plays effect jointly.The Pharmacological experiment result shows that the present invention has the function that to treat urarthritis well, having can Improve urarthritis caused by arthroncus, inflammatory factor change, Antioxidative Factors change etc. curative effect, can with pharmaceutically Acceptable carrier is prepared into various drug forms, facilitates clinic to take.Preparation method provided by the invention is workable, into This low, environmentally friendly, achievable industrialized production.
Embodiment
A. by golden cypress 10g, rhizoma atractylodis 10g, smilax 30g, radix glycyrrhizae 10g, root of Chinese clematis 15g, radix paeoniae rubrathe 10g, giant knotweed 15g, Radix Angelicae Sinensis 10g, edible tulip 8g, levisticum 10g, Radix Codonopsis 15g, prepared RADIX ET RHIZOMA RHEI with wine 10g, mixing, crush, be placed in round-bottomed flask, add 8 times of total raw material The pure water of amount, shaking mixing, soaks 30 minutes；
B. round-bottomed flask is connected into volatile oil extractor and reflux condensing tube, autocondensation pipe upper end adds water to be surveyed full of volatile oil Determine the scale part of device and when overflow enters round-bottomed flask untill, then round-bottomed flask is put boiling water is slowly heated in electric jacket And keep water micro-boiling 6 hours, stop heating, place cooling, open volatile oil extractor lower end piston, water is slowly released, receive Collect volatile oil, it is standby；
C. the dregs of a decoction after step b extraction volatile oil are taken, adds the pure water of 8 times of amounts to decoct 2 times, 2 hours every time, filtering, merges filter Liquid, be concentrated under reduced pressure to obtain water extract；
D. it is obtained volatile oil and water extract is well mixed.
Various drug forms can be prepared into pharmaceutically acceptable carrier
Experiment：
1. experiment packet
60 rats are randomly divided into 6 groups, respectively GA groups 10, colchicin group 10, blank control（NS）Group 10, this hair Bright embodiment low dose group 10, middle dose group of the embodiment of the present invention 10, high dose of embodiment of the present invention group 10.
1. experimental implementation
The μ l of 5% uric acid sodium solution of articulatio tibiotarsalis intracavitary administration 50 of each group Rat Right metapedes internal malleolus, establish rat urarthritis Model.The girth under Rat Right metapedes ankle-joint at 0.5mm is measured before modeling as 0h measured values, and continuous 8d points after modeling Other gavage gives medicine.Blank control（NS）Group gives physiological saline, and colchicin group is administered according to 1.5mg/kg, and the present invention is real A low dose group, middle dose group, high dose group are applied, basic, normal, high three concentration is administered respectively, concentration is respectively 1.5g/kg, 3g/ The % CMC-Na of kg, 6g/kg dissolution solvent 0.5, are taken twice daily, administered volume according to：1ml/100g.The 0h after modeling, 24h, 48h, 72h, 96h, 120h, 144h, 168h and 192h measure Rat Right metapedes ankle-joint perimeter value, observe Articular swelling Deng, in last dose take rat blood serum, arthritis be used for determine inflammatory parameters and Antioxidative Factors etc..
2. statistical method
All data are calculated using the softwares of SAS 9.2, and measurement data is represented with mean ± standard deviation（±S）, treat forward and backward difference Two groups of value or rate of change compare using Wei Shi sums of ranks（wilcoxon rank sum）Examine, effective percentage logic（logistic） Regression analysis.p<=0.05 will be regarded as being examined it is statistically significant.
3. experimental data and conclusion
（1）Articular swelling：Measuring method：With the wide paper slips of 2-3mm and four with after stainless steel dial caliper measurement each group Rat Right Perimeter value under sufficient articulatio talocruralis at 0.5mm.Swelling Index Definition：Surveyed by the wide paper slips of 2-3mm and four with stainless steel dial caliper Amount experiment is preceding and induces the joint Zhou Jing of different time after inflammation, and joint swelling index=（Minute point joint week, footpath one was initial Zhou Jing）/ initial Zhou Jing.Articular swelling can be used for alleviation degree of the evaluation medicine to urarthritis.
As a result it is as shown in table 1：
Table 1 increases rat different time points ankle-joint girth the influence of percentage（ ±SD）
As a result show：Each point in time, blank control group have significant difference with GA groups, illustrate modeling success.In 24h, the autumn Tazettine group and middle dose group of the embodiment of the present invention have significant difference with GA groups, illustrate in colchicin and the embodiment of the present invention Dosage group has therapeutic action.During 48h, middle dose group of the embodiment of the present invention has significant difference with GA groups, with blank control group There is no significant difference.During 72h, middle dose group of the embodiment of the present invention has significant difference with GA groups, with blank control group and autumn Tazettine group does not have significant difference.96h and after, middle dose group of the embodiment of the present invention, which has, to be alleviated urarthritis and becomes Gesture.
（2）Index determining in serum：
As a result it is as shown in table 2：
As a result show：
1. from the point of view of α NAG result, blank control group has significant difference with GA groups（p<0.05）, illustrate modeling success, and Can be as the index of drug evaluation；Colchicin group has the difference (p of conspicuousness with GA groups<0.01), colchicin group and blank Control group does not have significant difference, illustrates that colchicin has GA therapeutic action；Compared with GA groups, middle dose group has notable Difference (p<0.01), and compared with blank control group, middle dose group of the embodiment of the present invention is not significantly different, agent in explanation Measurer has reduction α NAG horizontal forces.
2. from the point of view of β-gal result, blank control group has significant difference with GA groups（p<0.01）, illustrate modeling into Work(, and can be as the index of drug evaluation；Colchicin group has the difference (p of conspicuousness with GA groups<0.01)；Compared with GA groups, High, middle dose group has significant difference (p<0.01), and compared with blank control group, colchicin group does not have with middle dose group Significant difference, illustrating that colchicin group is respectively provided with middle dosage reduces β-gal horizontal forces.
3. from the point of view of SOD result, blank control group has significant difference with GA groups（p<0.01）, illustrate modeling success, And can be as the index of drug evaluation；Colchicin group, middle dose group and GA groups have the difference (p of conspicuousness<0.01), with sky White control group does not have significant difference, illustrates colchicin and the significant increased SOD horizontal force of middle dosage.
4. from the point of view of UA result, blank control group has significant difference with GA groups（p<0.01）, illustrate modeling success, and Can be as the index of drug evaluation；Colchicin group, middle dose group and GA groups have the difference (p of conspicuousness<0.01), with blank Control group does not have significant difference, illustrates that colchicin and middle dosage significantly reduce UA horizontal forces.
（3）Index determining in joint fluid：
As a result such as table 3：
Table 3：
1. from the point of view of IL-6 result, blank control group has significant difference with GA groups（p<0.05）, illustrate modeling success, and Can be as the index of drug evaluation；Colchicin group, high, medium and low dosage group have the difference (p of conspicuousness with GA groups<0.05), And there is no significant difference with blank control group, illustrate that there is significant GA treatments to make for colchicin and each dosage Chinese medicine compound prescription With.Wherein middle dose group does not have significant difference with colchicin group, illustrates that both therapeutic actions are suitable.
2. from the point of view of IL-8 result, blank control group has significant difference with GA groups（p<0.05）, illustrate modeling into Work(, and can be as the index of drug evaluation；Middle dose group has the difference (p of conspicuousness with GA groups<0.05), and with blank pair According to no significant difference is organized, illustrate that middle dosage Chinese medicine compound prescription has significant GA therapeutic actions.
To sum up result shows：
Of the invention to have the function that to treat urarthritis well, swollen joint caused by urarthritis can be improved by having The curative effects such as swollen, inflammatory factor changes, Antioxidative Factors change.

Claims (2)

  1. A kind of 1. Chinese medicine for treating urarthritis, it is characterised in that it is to be made up of the volatile oil and water extract of Chinese herb medicine, The component and mass ratio of the Chinese herb medicine are as follows：Golden cypress 10, rhizoma atractylodis 10, smilax 30, radix glycyrrhizae 10, the root of Chinese clematis 15, the radix paeoniae rubrathe 10, Giant knotweed 15, Radix Angelicae Sinensis 10, edible tulip 8, levisticum 10, Radix Codonopsis 15, prepared RADIX ET RHIZOMA RHEI with wine 10.
  2. 2. a kind of preparation method of the medicine of the urarthritis for the treatment of as claimed in claim 1, it is characterised in that according to as follows Step is carried out：
    A. by raw material golden cypress, rhizoma atractylodis, smilax, radix glycyrrhizae, the root of Chinese clematis, the radix paeoniae rubrathe, giant knotweed, Radix Angelicae Sinensis, edible tulip, levisticum, Radix Codonopsis and wine Rheum officinale mixing, crush, be placed in round-bottomed flask, add the pure water of 8 times of amounts of total raw material, shaking mixing, soak 30 minutes；
    B. round-bottomed flask is connected into volatile oil extractor and reflux condensing tube, autocondensation pipe upper end adds water to be surveyed full of volatile oil Determine the scale part of device and when overflow enters round-bottomed flask untill, then round-bottomed flask is put boiling water is slowly heated in electric jacket And keep water micro-boiling 6 hours, stop heating, place cooling, open volatile oil extractor lower end piston, water is slowly released, receive Collect volatile oil, it is standby；
    C. the dregs of a decoction after step b extraction volatile oil are taken, adds the pure water of 8 times of amounts to decoct 2 times, 2 hours every time, filtering, merges filter Liquid, be concentrated under reduced pressure to obtain water extract；
    D. it is obtained volatile oil and water extract is well mixed.
CN201710796097.5A 2017-09-06 2017-09-06 Traditional Chinese medicine for treating gouty arthritis and preparation method Active CN107468955B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710796097.5A CN107468955B (en) 2017-09-06 2017-09-06 Traditional Chinese medicine for treating gouty arthritis and preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710796097.5A CN107468955B (en) 2017-09-06 2017-09-06 Traditional Chinese medicine for treating gouty arthritis and preparation method

Publications (2)

Publication Number Publication Date
CN107468955A true CN107468955A (en) 2017-12-15
CN107468955B CN107468955B (en) 2020-07-24

Family

ID=60584687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710796097.5A Active CN107468955B (en) 2017-09-06 2017-09-06 Traditional Chinese medicine for treating gouty arthritis and preparation method

Country Status (1)

Country Link
CN (1) CN107468955B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110384746A (en) * 2019-08-23 2019-10-29 江苏博润医疗集团有限公司 A kind of pharmaceutical composition and its preparation method and application preventing and treating gout
CN115814031A (en) * 2023-01-28 2023-03-21 广州中医药大学第三附属医院 Heat-clearing and detoxifying composition for treating gouty arthritis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1927330A (en) * 2006-09-05 2007-03-14 广州固志医药科技有限公司 Chinese medicine composition for treating gout and preparing method thereof
CN102579913A (en) * 2011-01-14 2012-07-18 天津市中宝制药有限公司 Traditional Chinese medicine composition for treating gouty arthritis
CN103239654A (en) * 2013-05-10 2013-08-14 钟映莉 Medicine for treating acute gouty arthritis
JP2014507476A (en) * 2011-03-11 2014-03-27 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド Methods and compositions for treating hyperuricemia and hyperuricemia-related metabolic disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1927330A (en) * 2006-09-05 2007-03-14 广州固志医药科技有限公司 Chinese medicine composition for treating gout and preparing method thereof
CN102579913A (en) * 2011-01-14 2012-07-18 天津市中宝制药有限公司 Traditional Chinese medicine composition for treating gouty arthritis
JP2014507476A (en) * 2011-03-11 2014-03-27 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド Methods and compositions for treating hyperuricemia and hyperuricemia-related metabolic disorders
CN103239654A (en) * 2013-05-10 2013-08-14 钟映莉 Medicine for treating acute gouty arthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘维等: "中药内服治疗痛风性关节炎规律分析", 《中华中医药杂志(原中国医药学报)》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110384746A (en) * 2019-08-23 2019-10-29 江苏博润医疗集团有限公司 A kind of pharmaceutical composition and its preparation method and application preventing and treating gout
CN115814031A (en) * 2023-01-28 2023-03-21 广州中医药大学第三附属医院 Heat-clearing and detoxifying composition for treating gouty arthritis
CN115814031B (en) * 2023-01-28 2023-06-23 广州中医药大学第三附属医院 Heat-clearing and detoxicating composition for treating gouty arthritis

Also Published As

Publication number Publication date
CN107468955B (en) 2020-07-24

Similar Documents

Publication Publication Date Title
CN103520497B (en) Chinese medicinal composition for treating gout and preparation method thereof
CN101991752A (en) Traditional Chinese medicine formula for treating gout
CN107468955A (en) Treat the Chinese medicine and preparation method of urarthritis
CN101485870A (en) Medicament for promoting digestion and expelling intestinal parasites
CN104800439A (en) Traditional Chinese medicine for treating chronic ulcerative colitis
CN101926896B (en) Traditional Chinese medicinal preparation for treating gout and preparation method thereof
CN104027684A (en) Traditional Chinese medicinal composition for treating gout and preparation method thereof
CN104258051B (en) Traditional Chinese medicine composition for treating gouty arthritis, and preparation method thereof
CN104162058A (en) Traditional Chinese medicine compound preparation for treating gout and preparation method thereof
CN101850063A (en) Medicinal preparation for preventing and treating gout and preparation method
CN108578606A (en) Treat the Chinese medicine preparation of rheumatoid arthritis
CN103735630B (en) A kind of Chinese medicine for the treatment of gout
CN103169745A (en) Traditional Chinese medicine composition for treating hematuria and application thereof
CN102145141A (en) Application of matching medicament to preparation of medicaments for treating chronic gout with gouty tophus
CN105147956A (en) Traditional Chinese medicine for treating acute peptic ulcer bleeding and preparation method of traditional Chinese medicine
CN104547923B (en) A kind of Chinese medicine composition for treating gouty nephropathy and its application
CN104873833A (en) Traditional Chinese medicine decoction for treating gouty arthritis
CN103638447A (en) Traditional Chinese medicine composition used for treating cholecystitis, and applications thereof
CN102940674B (en) Medicine composition for treating benign prostatic hyperplasia
CN114588233B (en) Composition for treating acute gout
CN102488804A (en) Traditional Chinese medicine for treating cirrhosis
CN1899428B (en) Chinese medicine preparation for treating pain and its preparing method
CN104922489B (en) A kind of Chinese medicine composition for treating chronic nephritis and preparation method thereof
CN106511631A (en) Qianlieping preparation used for treating prostatitis and preparation method thereof
CN101380414B (en) Traditional Chinese medicine composition for treating gout and hyperuricemia and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant